Mr. Sax is the managing member of a long short hedge fund based in Park City, UT. He has earned a national reputation for substantially outperforming the market in good times and bad. In addition to his financial acumen, Sax is recognized as a pioneer in the technology field. After several years at bulge bracket investment firms, he left to create one of the first publicly traded Internet companies and is also credited for creating the first web presence for numerous Fortune 1000 companies. Having sat at most seats at the investment table, Mr. Sax's view is uniquely shaped by his 360 perspective. He can be followed most closely at www.saxangle.com and on Twitter at www.twitter.com/saxangle.
My blog, Shastra (http://www.fiquant.wordpress.com/%20), is a commentary on Financial Markets from a Quantitative, Economic, Sociological and Azimovian perspective. I love exploring the dynamics behind financial markets from an Azimovian psycho-historical angle and observing the markets as it unfolds and affects the world around.
Evolution and Global Financial Markets are quite interesting and in a very crude sense, very similar. Survival of the fittest, various systems/philosophies playing each other out, sociological factors/variables interacting to form new dynamics, Hand of God (Governments/Central Banks!).
I intend to use this blog to publish some articles of finance and some of my own ideas about financial markets vis-a-vis evolution.
In Sanskrit, Shastra means knowledge which is based on principles that are held to be timeless. However, it also means a treatise or commentary written in explanation of an idea. In case ,you have not realized it already, "fiquant" is a play on piquant (meaning engagingly stimulating or provocative) and also indicates financial quant.
Dr. Schwartz is a 30-year veteran of the Pharmaceutical Industry most recently in the role of Executive Director, Strategic Transactions for Bristol-Myers Squibb Company where he has more than a dozen completed transactions to his credit. He speaks frequently on the Biotech-Big Pharma dynamics and evolving research and treatment paradigms in oncology and is perhaps best known for predicting FDA’s rejection of Dendreon’s Provenge vaccine in 2007 (San Francisco Chronicle, March 30, 2007). Provenge ultimately won FDA approval in April, 2010.
Dr. Schwartz founded RHS Advisors, LLC, a life-sciences consulting firm, in July 2010.
Asif Suria is an entrepreneur and investor with a focus on event driven strategies including merger arbitrage and insider trading. He publishes a weekly post that includes the latest mergers and highlights the largest spreads. He also publishes a weekly post that highlights the top 5 insider purchases and sales of the week.
Asif is also one of the earliest contributors at Seeking Alpha and has been regularly contributing content since 2005.
My name is Ivica Juracic and I’m the CEO and founder of Xpertstocktrader.com. I have been sharing my skills with hundreds of traders of every skill level since 2001. My method is simple, low risk, and consistently profitable. My system is based on an emphasis on simple, yet reliable technical signals. I focus upon stocks, ETFs, and FOREX and use few indicators. Instead I focus upon price action based upon the placement of a setup in the larger trend and use several tools to confirm my bias and locate high reward and low-risk trade setups.